OUTCOMES COMMITTEE AGENDA

结果委员会议程

• 批准号: 6099183
• 负责人: Lawrence JOSEPH WHEAT
• 金额: $ 14.14万
• 依托单位: INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
• 依托单位国家: 美国
• 财政年份: 1999
• 资助国家: 美国
• 起止时间: 1999-01-01 至 1999-12-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6099183
• 关键词: AIDS; AIDS therapy; HIV infections; behavioral /social science research tag; caregivers; clinical research; cooperative study; data collection methodology /evaluation; health care cost /financing; health care service evaluation; health care service utilization; health science research analysis /evaluation; human subject; human therapy evaluation; outcomes research; prognosis; therapy compliance

The Developmental Pharmacology Core will develop and implement assays for drugs used in patients with AIDS. These assays will be utilized to perform pharmacokinetic and drug interaction studies with dual goals of determining mechanisms of drug disposition and interaction and of providing clinical guidelines for design of optimal therapeutic regimens. This site will maintain a dynamic and flexible posture towards such studies; namely, though we plan specific projects, it is likely that availability of new drugs will provide the opportunity for important studies that cannot be anticipated at this time. Specific aims include: 1) To assess the determinants of renal excretion of DDI. 2) To assess the pharmacokinetic effects of ACT and DDI on each other. 3) To assess the elimination of DDI in patients with renal insufficiency. 4) To assess the pharmacokinetics of 8-aminoquinolones in HIV positive patients. 5) To assess phenotypes of metabolism of drugs used in patients with AIDS. 6) To assess stereoselective pharmacokinetics of drugs used in patients with AIDS.

发展药理学核心将开发和实施以下检测： 艾滋病患者使用的药物。 这些测定将用于执行 药代动力学和药物相互作用研究的双重目标是确定 药物处置和相互作用的机制以及提供临床 最佳治疗方案设计指南。 本网站将 对此类研究保持动态和灵活的态度；即， 尽管我们计划了具体项目，但很可能会出现新的项目 药物将为重要研究提供机会，而这些研究是无法进行的 预计此时。 具体目标包括： 1) 评估DDI肾脏排泄的决定因素。 2) 评估ACT和DDI相互之间的药代动力学影响。 3) 评估肾功能不全患者DDI的消除情况。 4) 评估 8-氨基喹诺酮类药物在 HIV 阳性患者中的药代动力学 患者。 5) 评估艾滋病患者所用药物的代谢表型。 6) 评估患者所用药物的立体选择性药代动力学 患有艾滋病。